Gilead Sciences (GILD) has posted triple-digit profit and sales growth in three of the past four quarters, thanks to blockbuster hepatitis C drugs Harvoni and Sovaldi. However, Q2 profit is expected to rise just 12% to $2.64 a share as comparisons to year-earlier quarters become more difficult. Sales are seen rising just 15% to $7.52 billion.